Influence of Stent Length on Periprocedural Outcomes After Primary Percutaneous Coronary Intervention in Patients with ST Segment Elevation Myocardial Infarction

References

• Collet J, Thiele H, Barbato E., et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Lawton J, Tamis-Holland J, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21–e129. doi:10.1016/j.jacc.2021.09.006
   PubMed Web of Science ®Google Scholar
• Choo E, Kim P, Chang K, et al. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality. Coron Artery Dis. 2014;25(5):392–398. doi:10.1097/mca.0000000000000108
   PubMed Web of Science ®Google Scholar
• Kim M, Cho J, Jeong H, et al. Long-Term Clinical Outcomes of Transient and Persistent No Reflow Phenomena following Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. Korean Circ J. 2016;46(4):490–498. doi:10.4070/kcj.2016.46.4.490
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383–2389. doi:10.1016/j.jacc.2009.12.054
   PubMed Web of Science ®Google Scholar
• Costa M, Angiolillo D, Tannenbaum M, et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol. 2008;101(12):1704–1711. doi:10.1016/j.amjcard.2008.02.053
   PubMed Web of Science ®Google Scholar
• Honda Y, Muramatsu T, Ito Y, et al. Impact of ultra-long second-generation drug-eluting stent implantation. Catheter Cardiovasc Interv. 2016;87(2):E44–53. doi:10.1002/ccd.26010
   PubMed Web of Science ®Google Scholar
• Chandrasekhar J, Baber U, Sartori S, et al. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018;11(1):53–65. doi:10.1016/j.jcin.2017.11.020
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Ganz W. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med. 1985;313(16):1018. doi:10.1056/nejm198510173131611
   PubMed Web of Science ®Google Scholar
• Gibson C, Cannon C, Daley W, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–888. doi:10.1161/01.cir.93.5.879
   PubMed Web of Science ®Google Scholar
• Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis. 2015;108(12):661–674. doi:10.1016/j.acvd.2015.09.006
   PubMed Web of Science ®Google Scholar
• Wijaya IP, Rumende CM, Nasution SA. The association between 24-h blood pressure variability and major adverse cardiac events (MACE) in hospitalized patients with acute myocardial infarction: a retrospective cohort study. Egypt Heart J. 2021;73(1):88. doi:10.1186/s43044-021-00213-1
   PubMedGoogle Scholar
• Kelshiker MA, Seligman H, Howard JP, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43(16):1582–1593. doi:10.1093/eurheartj/ehab775
   PubMed Web of Science ®Google Scholar
• Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66(4):403–469. doi:10.1016/j.jacc.2014.12.018
   PubMed Web of Science ®Google Scholar
• Durante A, Camici P. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol. 2015;187:273–280. doi:10.1016/j.ijcard.2015.03.359
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281–292. doi:10.1016/j.jacc.2009.03.054
   PubMed Web of Science ®Google Scholar
• Salinas P, Jimenez-Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem. 2012;10(3):256–264. doi:10.2174/187152512802651024
   PubMedGoogle Scholar
• Ejiri K, Sawano M, Numasawa Y, et al. Association of Second-Generation Drug-Eluting Stent Length With 2-Year Adverse Clinical Outcomes Among Japanese Patients With Ischemic Heart Disease. JAMA Network Open. 2020;3(8):e2012546. doi:10.1001/jamanetworkopen.2020.12546
   PubMed Web of Science ®Google Scholar
• Wu G, Zong G, Chen J, et al. Changes of plasma B-type natriuretic peptide levels after high-pressure post-dilation following coronary stent deployment. PLoS One. 2013;8(12):e82357. doi:10.1371/journal.pone.0082357
   PubMed Web of Science ®Google Scholar
• Kleinbongard P, Böse D, Baars T, et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2011;108(3):344–352. doi:10.1161/circresaha.110.235713
   PubMed Web of Science ®Google Scholar
• Kurtul A, Murat SN, Yarlioglues M, Duran M, Celik IE, Kilic A. Mild to Moderate Renal Impairment Is Associated With No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Angiology. 2015;66(7):644–651. doi:10.1177/0003319714546738
   PubMed Web of Science ®Google Scholar
• Namazi M, Mahmoudi E, Safi M, et al. The No-reflow Phenomenon: is it Predictable by Demographic factors and Routine Laboratory Data? Acta Biomed. 2021;92(5):e2021297. doi:10.23750/abm.v92i5.10053
   PubMedGoogle Scholar
• Zhao SR, Huang R, Liu F, Li Y, Gong Y, Xing J. Study on Correlation between Type 2 Diabetes and No-Reflow after PCI. Dis Markers. 2022;2022:7319277. doi:10.1155/2022/7319277
   PubMed Web of Science ®Google Scholar
• Reindl M, Reinstadler SJ, Feistritzer HJ, et al. Relation of Low-Density Lipoprotein Cholesterol With Microvascular Injury and Clinical Outcome in Revascularized ST-Elevation Myocardial Infarction. J Am Heart Assoc. 2017;6(10):48. doi:10.1161/jaha.117.006957
   Web of Science ®Google Scholar
• Zhao JL, Yang YJ, Pei WD, Sun YH, Chen JL. The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. Am J Cardiovasc Drugs. 2009;9(2):81–89. doi:10.1007/bf03256579
   PubMed Web of Science ®Google Scholar
• Karamasis GV, Kalogeropoulos AS, Gamma RA, et al. Effects of stent postdilatation during primary PCI for STEMI: insights from coronary physiology and optical coherence tomography. Catheter Cardiovasc Interv. 2021;97(7):1309–1317. doi:10.1002/ccd.28932
   PubMed Web of Science ®Google Scholar
• Naidu S, Krucoff M, Rutledge D, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8061-patient XIENCE V United States study. JACC Cardiovasc Interv. 2012;5(6):626–635. doi:10.1016/j.jcin.2012.02.014
   PubMed Web of Science ®Google Scholar
• Shirai S, Kimura T, Nobuyoshi M, et al. Impact of multiple and long sirolimus-eluting stent implantation on 3-year clinical outcomes in the j-Cypher Registry. JACC Cardiovasc Interv. 2010;3(2):180–188. doi:10.1016/j.jcin.2009.11.009
   PubMed Web of Science ®Google Scholar
• Suh J, Park D, Lee J, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv. 2010;3(4):383–389. doi:10.1016/j.jcin.2009.10.033
   PubMed Web of Science ®Google Scholar
• Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–1393. doi:10.1016/s0735-1097(03
   PubMed Web of Science ®Google Scholar
• Li XD, Yang YJ, Hao YC, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J. 2013;126(9):1755–1760.
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv. 2017;10(3):215–223. doi:10.1016/j.jcin.2016.11.059
   PubMed Web of Science ®Google Scholar
• Egred M, Bagnall A, Spyridopoulos I, et al. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: piCSO in ACS study. Int J Cardiol Heart Vasc. 2020;28:100526. doi:10.1016/j.ijcha.2020.100526
   PubMed Web of Science ®Google Scholar